Channel News Asia  Jun 11  Comment 
A group of Takeda Pharmaceutical Co Ltd shareholders is building support to block the US$62 billion acquisition of London-listed Shire Plc at an extraordinary general meeting, a leading member of the group told Reuters on Monday.
FierceBiotech  Jun 7  Comment 
Trillium Therapeutics has named Yaping Shou, M.D., Ph.D., as its CMO. Shou joins the anti-CD7 cancer biotech from Takeda’s oncology department, where she worked as executive medical director.
Financial Times  Jun 5  Comment 
Dissident group has little voting clout but carries influence of founding family members
FiercePharma  Jun 1  Comment 
A group of 12 Takeda shareholders demand a vote on the Shire deal out of fear for "high risks"; WuXi AppTec becomes the largest-cap CRO after its stock jumped sixfold in three weeks since listing in Shanghai; Gardasil franchise's Chinese nods...
FiercePharma  May 29  Comment 
Takeda's shares have lost more than 20% of their value since late March, when the company first announced its intention to buy Shire. That loss of market value is being cited by a group of 12 shareholders stepping up to oppose the deal.
FiercePharma  May 18  Comment 
China's WuXi Biologics and Sinobioway are investing hundreds of millions of dollars on biologics facilities; Takeda sees 40% drop in Velcade sales for 2018 and is looking to offload "moderately innovative" assets in its pipeline to cut costs; and...
Wall Street Journal  May 9  Comment 
Making a $62 billion acquisition work for your investors isn’t easy, but the odds of success for Takeda Pharmaceuticals with Shire are higher than the market currently thinks.
GenEng News  Apr 25  Comment 
Shire’s board last night set the stage for a potential Takeda acquisition by saying it would recommend to shareholders approval of Takeda’s approximately £46 billion ($64 billion) offer for the company—if other terms can be worked out. ...


No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki